

# Protein-passivated Fe<sub>3</sub>O<sub>4</sub> nanoparticles: low toxicity and rapid heating for thermal therapy†

Bappaditya Samanta,<sup>‡a</sup> Haoheng Yan,<sup>‡b</sup> Nicholas O. Fischer,<sup>b</sup> Jing Shi,<sup>a</sup> D. Joseph Jerry<sup>c</sup> and Vincent M. Rotello<sup>\*a</sup>

Received 4th December 2007, Accepted 23rd January 2008

First published as an Advance Article on the web 19th February 2008

DOI: 10.1039/b718745a

Thermotherapy is a promising technique for the minimally invasive elimination of solid tumors. Here we report the fabrication of protein-coated iron oxide NPs (12 nm core) for use as thermal therapeutic agents. These albumin-passivated NPs are stable under physiological conditions, with rapid heating and cell killing capacity upon alternating magnetic field (AMF) exposure. The mode of action is specific: no measurable cytotoxicity was observed for the particle without AMF or for AMF exposure without the particle.

## Introduction

Conventional surgical treatment is effective in treating most primary tumors. However, it is of limited utility for small, poorly defined recurrences, metastases, and tumors embedded within vital regions. In these situations, directed therapy with minimum invasion and less morbidity are required. Thermal ablation therapies that use directed heating to ablate malignant tissues provide a minimally invasive alternative to conventional surgical treatments.<sup>1</sup> Current conventional strategies for thermal therapy include laser,<sup>2,3</sup> focused ultrasound,<sup>4</sup> microwave<sup>5</sup> or radiofrequency probes<sup>6</sup> that can be placed in lesions. While useful, the use of macroscopic heating systems can limit the affected tumor volumes and damage normal tissue adjacent to the tumor and between the target and the probe.<sup>3,7</sup>

New approaches have been investigated that separate the energy source from the heating source, including pulsed laser,<sup>8</sup> infrared<sup>9,10</sup> and magnetic field induced thermal therapy.<sup>11,12</sup> For example, metal nanoshells,<sup>9</sup> nanorods,<sup>10a</sup> carbon nanotubes<sup>10b</sup> provide selective heating to tissues upon exposure to intense near-infrared laser irradiation (NIR) from outside the body. The moderate penetration depth of NIR, however, limits the utility of this method in treating deep lesions in the body.

Magnetic thermal therapy uses an alternating magnetic field (AMF) to heat particles embedded within tissue. Tissue is essentially transparent to magnetic fields, and even quite strong fields are harmless to tissue.<sup>13</sup> Iron oxide NPs have been shown to heat effectively using AMF, in systems including NP-loaded liposomes,<sup>14</sup> magnetite-doped microspheres, and magnetic fluids (ferrofluids).<sup>15</sup> Dextran<sup>16,17</sup> and aminosilane<sup>18</sup> coated iron oxide

nanoparticles have been studied *in vivo* for use in cancer therapy. Large amounts of these studies used polydisperse NPs, resulting in diminished heating efficiency<sup>19</sup> and the requirement of either high particle concentrations (with concomitant toxicity) or high magnetic field strength with concomitant nonspecific tissue heating to achieve therapeutic effects.<sup>20</sup>

Here, we report the synthesis of protein-coated iron oxide NPs (MNP-A) featuring efficient heating and very low inherent cytotoxicity (Fig. 1a). The narrow size distribution of the iron oxide core (diameter = 12 nm) ensures high heating capabilities in low concentrations under biocompatible AMF conditions. The protein coating features albumin as a protective layer on the NP, imparting stability, water solubility and biocompatibility under physiological conditions. Moreover, albumins have




Fig. 1 (a) Synthesis and structure of MNP-A; (b) TEM micrograph of MNP-A.

<sup>a</sup>Department of Chemistry, University of Massachusetts, USA. E-mail: rotello@chem.umass.edu; Fax: +413-545-4490; Tel: +413-545-2058

<sup>b</sup>Molecular and Cellular Biology Program, University of Massachusetts, USA

<sup>c</sup>Department of Veterinary and Animal Science, University of Massachusetts, USA

† Electronic supplementary information (ESI) available: Histogram, TGA and stability assay data of nanoparticles. See DOI: 10.1039/b718745a


‡ These authors contributed equally to this work.

multiple surface lysine groups that can be used as a scaffold for the chemical attachment of targeting groups.<sup>21</sup>

## Results and discussion

We employed a modification of Massart's co-precipitation method<sup>22</sup> to provide 'naked' NPs suitable for facile functionalization. Bovine serum albumin (BSA) passivation of the iron oxide core was performed *via* ultrasonication of the particle in the presence of excess BSA (see Experimental section for details). BSA coated iron oxide (MNP-A) NPs were isolated from excess BSA solution *via* ultracentrifugation. The TEM micrograph of MNP-A NPs reveal the NP core is  $12.1 \pm 1.6$  nm in diameter (Fig. 1b).

BSA is an anionic protein with a pI of 4.8, so it is likely that adsorption of the BSA onto the NP occurs through anionic functionality of the BSA, as previous studies show that carboxylate groups provide excellent ligation for iron oxide NPs.<sup>23,24</sup> The presence of BSA on the NP surface was confirmed by Fourier transform infrared (FT-IR) spectroscopy, as the characteristic bands of the BSA protein at  $1660\text{ cm}^{-1}$  and  $1530\text{ cm}^{-1}$  are both present in the FT-IR spectra of MNP-A (Fig. 2a). In addition, thermogravimetric analysis (TGA) was conducted to quantify




**Fig. 2** Characterization of MNP-A: (a) FT-IR spectrum of BSA (blue), iron oxide core (black) and MNP-A (green). (b) Circular dichroism spectra of BSA, MNP-A and thermally denatured BSA.

the amount of adsorbed BSA. The 22.5% weight loss observed from TGA of MNP-A (see ESI, Fig. S3†) corresponds to  $\sim 13$  BSA molecules per iron oxide core. The adsorption of BSA to the NP core results in partial denaturation of the protein (Fig. 2b). Considering the size of BSA (8.4 nm),<sup>25</sup> the thickness of the protein shell on the nanoparticle would be  $\sim 8$  nm, therefore the overall diameter of MNP-A would be  $\sim 28$  nm.

In aqueous solution, the average hydrodynamic size of MNP-A is  $50 \pm 5$  nm, measured by dynamic light scattering (DLS) (Fig. 3). The increase in hydrodynamic diameter of MNP-A suggests that there is minor particle aggregation. MNP-A showed excellent long-term solution stability, remaining stable in deionized water for more than 2 months. No aggregation was observed under a variety of conditions, including deionized water, and cell culture medium (see ESI, Fig. S4† for stability assay of MNP-A). As expected, due to the overall negative charge of BSA, MNP-A is negatively charged with a  $\zeta$ -potential of  $-25$  mV.

Application of iron oxide NPs in thermal therapy depends on the heating efficiency of NPs, which is assessed by the surface absorption rate (SAR).<sup>26</sup> The SAR is dependent on particle size, size distribution in a real sample [assigned as standard deviation (SD)], field frequency<sup>27</sup> and amplitude<sup>28</sup> of the AMF. As a comparison, water-soluble anionic citrate coated iron oxide (MNP-B) NPs were synthesized<sup>29</sup> and magnetic separation<sup>30</sup> of larger size NPs was performed to show the effect of NP size and SD on SAR. As synthesized MNP-B NPs (sample diameter  $d_0 = 10.4$  nm, SD = 2.3, see ESI, Fig. S1a†) have an SAR of  $5.2\text{ W g}_{\text{iron oxide}}^{-1}$  at an AMF amplitude of  $6.3\text{ kAm}^{-1}$  and frequency of 400 kHz. In contrast, the SAR of magnetically separated MNP-B NPs ( $d_0 = 12.4$  nm, SD = 2.1, see ESI, Fig. S1b†) were enhanced to  $20\text{ W g}_{\text{iron oxide}}^{-1}$  (Table 1).

Hergt *et al.*<sup>31</sup> and Fortin *et al.*<sup>19</sup> also obtained similar results after magnetic separation of dextran-coated particles and size selective precipitation of citrate coated iron oxide NPs respectively. The BSA coated iron oxide (MNP-A) NPs improved the SAR. Without magnetic separation or size selective precipitation, MNP-A ( $d_0 = 12.1$  nm, SD = 1.6, Fig. 1b and see ESI, Fig. S2† for particle size histograms) showed a higher SAR of



**Fig. 3** DLS analysis of MNP-A. Inset, photograph of MNP-A NPs in water and media after 24 h incubation. MNP-A shows no precipitation in media or water.

**Table 1** NPs synthesized for AMF therapy, with their measured SAR in a magnetic field of amplitude  $H = 6.3 \text{ kA m}^{-1}$  and frequency  $f = 400 \text{ kHz}$

	MNP-A	MNP-B	
$d_0$	12.1 nm	10.4 nm	12.2 nm
SD	1.6 nm	2.3 nm	2.1 nm
SAR	$36 \text{ W g}_{\text{iron oxide}}^{-1}$	$5.2 \text{ W g}_{\text{iron oxide}}^{-1}$	$20 \text{ W g}_{\text{iron oxide}}^{-1}$

$36 \text{ W g}_{\text{iron oxide}}^{-1}$  even compared to magnetically separated **MNP-B**. The observed better SAR is likely to be due to a combination of the narrower size distribution of **MNP-A** and the surface structure of the material.

We investigated the heating of bulk water using **MNP-A**. In less than 2 min, a temperature increase of  $> 40 \text{ }^\circ\text{C}$  was observed in a  $100 \text{ mg mL}^{-1}$  solution of **MNP-A** using  $400 \text{ kHz}$ ,  $6.3 \text{ kA m}^{-1}$  AMF.

With bulk heating established, we next explored the interaction of **MNP-A** with cells. Perls Prussian blue staining of **MNP-A**-treated Hela cells revealed a high density of

nanoparticles on the cell surface (Fig. 4a). Thermoablation by **MNP-A** particles was also tested in cultured cancer cells. Hela cells were incubated with **MNP-A** for 2 h followed by 45 min of magnetic field exposure ( $400 \text{ kHz}$ ,  $6.3 \text{ kA m}^{-1}$ ). As a control, cells were also treated with **MNP-A** alone or AMF alone, or media only. Immediately after treatment, cytotoxicity was measured among the treatments. The cells incubated with NP concentrations of more than  $4 \text{ mg mL}^{-1}$  subjected to the magnetic field showed total cell death after treatment, whereas cells that were treated with particles but without exposing to the magnetic field were unaffected, even at much higher NP concentrations (Fig. 4b). As expected, control cells that were exposed to the magnetic field in the absence of NPs showed no decrease in the cell viability. In this experimental setup, cancers cells were abolished by the temperature rise due to **MNP-A** heating under AMF. It demonstrates that **MNP-A** provides a selective tool for AMF-induced ablation, as well as useful dosing information for future animal study.

## Conclusions

In summary, we have developed a non-toxic iron oxide NP that employs BSA as a biocompatible passivating agent. Ultrasonication provides a simple tool for passivating BSA onto NPs. This approach can be extended to other proteins and small molecules. This particle is stable in a variety of media, and provides very rapid and efficient heating under AMF conditions. **MNP-A** is a highly selective thermal ablation agent, with no cytotoxicity observed in the absence of AMF. The BSA coating provides a platform for future incorporating targeting molecules to realize targeted tumor thermal therapy for animal study, a prospect that is currently under investigation.


## Experimental section

### Materials

Albumin from bovine serum (BSA) was purchased from Sigma-Aldrich. All other starting materials were purchased from Fisher Scientific and were used without further purification unless otherwise specified. Aquasonic (Model 150 T) ultrasonic cleaner was purchased from VWR scientific products.

### Albumin coated iron oxide NPs synthesis

$\text{Fe}_3\text{O}_4$  NPs were synthesized under alkaline conditions, while maintaining a molar ratio of  $\text{Fe}^{2+} : \text{Fe}^{3+} = 1 : 2$  in argon.  $0.86 \text{ g}$  of  $\text{FeCl}_2 \cdot 4 \text{ H}_2\text{O}$  and  $\text{FeCl}_3 \cdot 6 \text{ H}_2\text{O}$  were dissolved under an argon atmosphere in  $40 \text{ mL}$  of deionized water with vigorous stirring. The solution was purged with argon for 5 min to remove any oxygen present in the deionized water. A black precipitate was formed after the addition of  $\text{NH}_4\text{OH}$  ( $10 \text{ mL}$ ) to the reaction mixture. The pH of the reaction mixture was maintained at  $\sim 10$ – $12$ . The black precipitate was incubated at  $90 \text{ }^\circ\text{C}$  for 20 min. Then the reaction mixture was cooled down to room temperature and washed with deionized water three times to remove unreacted chemicals and decrease the pH of the solution.  $1 \text{ g}$  bovine serum albumin (BSA), which was dissolved in  $20 \text{ mL}$  water, was added to the NP precursor in argon. Then the reaction mixture was sonicated (using an Aquasonic ultrasonic



**Fig. 4** (a) Micrographs show interaction of **MNP-A** with cultured Hela cells. Cells were incubated in medium with **MNP-A** or without, followed by Perls Prussian blue staining. **MNP-A** appeared as a blue precipitate on the cell cytoplasm (left) while no iron was detected in the control (right). (b) Thermal effect of **MNP-A** on cell culture. Hela cells were incubated with **MNP-A** for 2 h followed by 45 min magnetic field exposure. After AMF exposure, cells were immediately washed by PBS twice and subjected to a cell viability (10% alamar blue reduction) assay, with cell death being confirmed by trypan blue staining (data not shown). Inset: Toxicity at  $4 \text{ mg mL}^{-1}$  **MNP-A**.

cleaner) for 2.5 h. A clear reddish-brown color solution was formed. Excess BSA was removed by ultracentrifugation at 50 000 rpm for 30 min. The process was repeated twice, and the pellet of **MNP-A** was dissolved in milliQ water.

### Transmission electron microscopy (TEM) and determination of the particles' size distribution

TEM images were acquired on a JEOL 100CX operating at 100 keV. Samples were drop cast from water solution, onto a copper-coated grid, dried, and imaged. The particles' size distribution, assigned as the standard deviation (SD), was measured using imageJ software.


### Experimental setup for magnetic thermal therapy

An alternating magnetic field (AMF) heating system was purchased from MSI Automation, Inc. (Wichita, Kansas, USA). The experiment was performed inside a copper coil (diameter 10 cm), which produces an AMF at a fixed frequency of 400 kHz and fixed amplitude of  $6.3 \text{ kA m}^{-1}$ . The experimental setup is depicted in Fig. 5a. The temperature of the sample holder was maintained at  $37 \pm 0.5 \text{ }^\circ\text{C}$  by using a deltapulse isothermal pad. The temperature for the experiments was measured by a DualLogR thermocouple thermometer (Eutech Instruments Pte Ltd, Singapore) with a TEF-30-T thermocouple (J-KEM Scientific, Inc. St. Louis, MO, USA). The initial linear rise in temperature versus time dependence,  $dT/dt$ , was measured as illustrated in Fig. 5b. The specific absorption rate (SAR) is defined as follows.

$\text{SAR} = (C_{\text{water}}/c)dT/dt$ , where  $C_{\text{water}}$  is the specific heat capacity of water and has the numeric value corresponding to  $4185 \text{ J L K}^{-1}$ ,  $c$  is the sample concentration in  $\text{g L}^{-1}$ .

### Dynamic light scattering (DLS) and $\zeta$ -potential

DLS samples were prepared using 5 mM sodium phosphate buffer (pH = 7.4) and in milliQ water filtered with Acrodisc 0.2  $\mu\text{m}$  filters (Pall Gelman Laboratory, Ann Arbor, MI). The NPs' concentration was  $\sim 1 \text{ mg mL}^{-1}$ . Samples for  $\zeta$ -potentials were prepared using 5 mM sodium phosphate buffer (pH = 7.4) with filtration. Both the measurements were performed on a Malvern Zetasizer Nano ZS instrument. Reported values of data are averages of nine measurements.



**Fig. 5** (a) Schematics of the AMF device for alternating magnetic field thermal therapy. (b) SAR was measured by using the initial slope of  $dT/dt$ .

### Infrared spectroscopy

IR spectra were taken of KBr pellets formed from dry powder samples of BSA, iron oxide precursor and **MNP-A** using a MIDAC M1200-SP3 spectrophotometer.

### Circular dichroism (CD)

Far-UV CD spectra of BSA, thermally denatured BSA and **MNP-A** were measured on a JASCO J-720 spectropolarimeter with quartz cuvettes of 1 mm path length at  $25 \text{ }^\circ\text{C}$ . The spectra were recorded from 190 to 250 nm as an average of three scans at a rate of  $10 \text{ nm min}^{-1}$ .

### Cell culture

Hela cells were grown in a RPMI1640 medium (Gibco BRL) supplemented with 10% fetal bovine serum (Gibco BRL), MEM non-essential amino acids (Sigma), sodium pyruvate (1 mM), sodium bicarbonate (0.15%, w/v) and antibiotic-antimycotic solution ( $100 \mu\text{g mL}^{-1}$  penicillin +  $100 \mu\text{g mL}^{-1}$  streptomycin +  $0.25 \mu\text{g mL}^{-1}$  amphotericin B) in an atmosphere of 5%  $\text{CO}_2$  at  $37 \text{ }^\circ\text{C}$ .

### Cell staining

Hela cells were incubated in **MNP-A** ( $4 \text{ mg mL}^{-1}$ ) containing medium for 2 h under cell culture conditions. After washing with PBS, cells were fixed with methanol at  $-20 \text{ }^\circ\text{C}$ , washed with PBS, incubated for 15 min in a solution of 2% potassium ferrocyanide in 2% HCl, washed, and counter stained with eosin.

### Thermal effect of **MNP-A** on cell culture

$8 \times 10^4$  Hela cells well $^{-1}$  were seeded in 4 well plates (200 mm $^2$  well $^{-1}$ ) and incubated overnight. Then the culture medium was replaced by **MNP-A** containing medium for 2 h followed by 45 min magnetic field exposure. After AMF exposure, cells were immediately washed by PBS twice and subjected to cell viability assay.

### Cell viability assay

Cell viability was measured by quantifying the reduction of a dye indicator alamar blue. Alamar blue is a dye that takes advantage of mitochondrial reductases to change from oxidized indigo blue state to reduced pink state. This dye has been successfully used in various cell cultures to measure cell viability.<sup>32,33</sup> Briefly, cells in 4 well plates are loaded with 300  $\mu\text{L}$  culture medium containing 10% alamar blue (Biosource International) and incubated in  $37 \text{ }^\circ\text{C}$ , 5%  $\text{CO}_2$  for 2 h. 100  $\mu\text{L}$  medium from each well was then transferred to a 96 well plate and subjected to measurement. The reduction of alamar blue was measured and calculated by a SpectroMax M5 micro-plate reader (Molecular Device) at 570 nm and 600 nm wavelengths.


### Acknowledgements

We thank Robert E. Sabola for instrument management. This research was funded by the UMass Center of Excellence in Apoptosis Research (CEAR), Army Breast Cancer Research

Program (DAMD17-03-1-0419 and DAMD17-03-1-0257 to NF) and the NSF Center for Hierarchical Manufacturing at the University of Massachusetts (NSEC, DMI-0531171).

## References

- (a) S. B. Field and C. C. Morris, *Radiother. Oncol.*, 1983, **1**, 179; (b) S. A. Sapareto and W. C. Dewey, *Int. J. Radiat. Oncol. Biol. Phys.*, 1984, **10**, 787; (c) C. J. Diederich, *Int. J. Hyperthermia*, 2005, **21**, 745.
- (a) Z. Amin, J. J. Donald, A. Masters, R. Kant, A. C. Steger, S. G. Bowlin and W. R. Lees, *Radiology*, 1993, **187**, 339; (b) T. J. Vogl, R. Straub, S. Zangos, M. G. Mack and K. Eichler, *Int. J. Hyperthermia*, 2004, **20**, 713.
- T. J. Vogl, M. G. Mack, P. K. Muller, R. Straub, K. Engelmann and K. Eichler, *Eur. Radiol.*, 1999, **9**, 1479.
- (a) F. A. Jolesz and K. Hynynen, *Cancer J.*, 2002, **8**, S100; (b) N. McDannold, C. M. Tempny, F. M. Fennessy, M. J. So, F. J. Rybicki, E. A. Stewart, F. A. Jolesz and K. Hynynen, *Radiology*, 2006, **240**, 263.
- T. Seki, M. Wakabayashi, T. Nakagawa, M. Imamura, T. Tamai, A. Nishimura, N. Yamashiki, A. Okamura and K. Inoue, *Cancer*, 1999, **85**, 1694.
- G. S. Gazelle, S. N. Goldberg, L. Solbiati and T. Livraghi, *Radiology*, 2000, **217**, 633.
- K. U. Kohrmann, M. S. Michel, J. Gaa, E. Marlinghaus and P. Alken, *J. Urol.*, 2002, **167**, 2397.
- V. S. Kalambur, E. K. Longmire and J. C. Bischof, *Langmuir*, 2007, **23**, 12329.
- (a) L. R. Hirsch, R. J. Stafford, J. A. Bankson, S. R. Sershen, B. Rivera, R. E. Price, J. D. Hazle, N. J. Halas and J. L. West, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**, 13549; (b) C. Loo, A. Lowery, N. J. Halas, J. L. West and R. Drezek, *Nano Lett.*, 2005, **5**, 709–711.
- (a) X. H. Huang, I. H. El-Sayed, W. Qian and M. A. El-Sayed, *J. Am. Chem. Soc.*, 2006, **128**, 2115–2120; (b) N. W. S. Kam, M. O'Connell, J. A. Wisdom and H. J. Dai, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 11600–11605; (c) D. Boyer, P. Tamarat, A. Maali, B. Lounis and M. Orrit, *Science*, 2002, **297**, 1160–1163.
- (a) A. Jordan, R. Scholz, P. Wust, H. Fahling and R. Felix, *J. Magn. Magn. Mater.*, 1999, **201**, 413; (b) I. Hilger, R. Hergt and W. A. Kaiser, *J. Magn. Magn. Mater.*, 2005, **293**, 314.
- S. Mornet, S. Vasseur, F. Grasset and E. Duguet, *J. Mater. Chem.*, 2004, **4**, 2161.
- I. Hilger, R. Hergt and W. A. Kaiser, *IEE Proc. Nanobiotechnol.*, 2005, **152**, 33.
- (a) A. Ito, M. Shinkai, H. Honda and T. Kobayashi, *J. Biosci. Bioeng.*, 2005, **100**, 1–11; (b) N. Kawai, A. Ito, Y. Nakahara, H. Honda, T. Kobayashi, M. Futakuchi, T. Shirai, K. Tozawa and K. Kohri, *Prostate*, 2006, **66**, 718–727.
- P. Drake, H.-J. Cho, P.-S. Shih, C.-H. Kao, K.-F. Lee, C.-H. Kuo, X.-Z. Lin and Y.-J. Lin, *J. Mater. Chem.*, 2007, **17**, 4914.
- A. Jordan, R. Scholz, P. Wust, H. Fahling, J. Krause, W. Wlodarczyk, B. Sander, T. Vogl and R. Felix, *Int. J. Hyperthermia*, 1997, **13**, 587.
- S. J. DeNardo, G. L. DeNardo, L. A. Miers, A. Natarajan, A. R. Foreman, C. Gruettner, G. N. Adamson and R. Ivkov, *Clin. Cancer Res.*, 2005, **11**, 7087S.
- A. Jordan, R. Scholz, P. Wust, H. Schirra, T. Schiestel, H. Schmidt and R. Felix, *J. Magn. Magn. Mater.*, 1999, **194**, 185.
- J.-P. Fortin, C. Wilhelm, J. Servais, C. Menager, J.-C. Bacri and F. Gazeau, *J. Am. Chem. Soc.*, 2007, **129**, 2628–2635.
- R. Ivkov, S. J. DeNardo, W. Daum, A. R. Foreman, R. C. Goldstein, V. S. Nemkov and G. L. DeNardo, *Clin. Cancer Res.*, 2005, **11**, 7093S.
- (a) A. G. Tkachenko, H. Xie, D. Coleman, W. Glomm, J. Ryan, M. F. Anderson, S. Franzen and D. L. Feldheim, *J. Am. Chem. Soc.*, 2003, **125**, 4700; (b) J. L. Burt, C. Gutierrez-Wing, M. Miki-Yoshida and M. Jose-Yacamán, *Langmuir*, 2004, **20**, 11778; (c) A. V. Singh, B. M. Bandgar, M. Kasture, B. L. V. Prasad and M. Sastry, *J. Mater. Chem.*, 2005, **15**, 5115; (d) H. Xie, A. G. Tkachenko, W. R. Glomm, J. A. Ryan, M. K. Brennaman, J. M. Papanikolas, S. Franzen and D. L. Feldheim, *Anal. Chem.*, 2003, **75**, 5797.
- R. Massart, *IEEE Trans. Magn.*, 1981, **MAG-17**, 1247.
- J. Park, K. J. An, Y. S. Hwang, J. G. Park, H. J. Noh, J. Y. Kim, J. H. Park, N. M. Hwang and T. Hyeon, *Nat. Mater.*, 2004, **3**, 891–895.
- S. H. Sun, H. Zeng, D. B. Robinson, S. Raoux, P. M. Rice, S. X. Wang and G. X. Li, *J. Am. Chem. Soc.*, 2004, **126**, 273.
- M. L. Ferrer, R. Duchowicz, B. Carrasco, J. G. de la Torre and A. U. Acuna, *Biophys. J.*, 2001, **80**, 2422–2430.
- The specific absorption rate (SAR) is defined as follows:  $SAR = (C_{\text{water}}/c)dT/dt$ , where  $C_{\text{water}}$  is the specific heat capacity of water and has the numeric value corresponding to  $4185 \text{ J L K}^{-1}$ ,  $c$  is the sample concentration in  $\text{g L}^{-1}$ ,  $dT/dt$  is the initial linear rise in temperature versus time dependence.
- The SAR increases linearly with frequency for NPs with a characteristic diameter below 10 nm and saturated with larger particles. The fact of negligible dependency with frequency of SAR for these iron oxide nanoparticles is due to the bigger average size ( $>10 \text{ nm}$ ).
- The SAR varied with the square of the magnetic field amplitude (H) in samples,  $SAR \approx H^2$ . H was fixed for the available instrument at  $6.3 \text{ kA m}^{-1}$ .
- R. Sheparovych, Y. Sahoo, M. Motornov, S. Wang, H. Luo, P. N. Prasad, I. Sokolov and S. Minko, *Chem. Mater.*, 2006, **18**, 591–593.
- MNP-B colloidal solution was placed on top of a permanent magnet (1.2 T) for 6 h. Most of the particles were collected in the bottom of the glass vial leaving a small fraction in the solution. The sediment fraction ( $SD = 2.1$ ) was redispersed in water.
- R. H. R. Hergt, M. Zeisberger, G. Glöckl, W. Weitschies, L. P. Ramirez, I. Hilger and W. A. Kaiser, *J. Magn. Magn. Mater.*, 2004, **280**, 358–368.
- S. Liu, K. Kawai, V. A. Tyurin, Y. Y. Tyurina, G. G. Borisenko, J. P. Fabisiak, P. J. Quinn, B. R. Pitt and V. E. Kagan, *Biochem. J.*, 2001, 397.
- E. R. Grant, M. A. Errico, S. L. Emanuel, D. Benjamin, M. K. McMillian, S. A. Wadsworth, R. A. Zivin and Z. Zhong, *Biochem. Pharmacol.*, 2001, **62**, 283.



Showcasing collaborative research from the  
D. Joseph Jerry and Vincent Rotello labs,  
University of Massachusetts, Amherst.

**Title: Protein-passivated Fe<sub>3</sub>O<sub>4</sub> nanoparticles: low toxicity  
and rapid heating for thermal therapy**

Passivation with albumin provides iron oxide nanoparticles that are stable under physiological conditions. These particles heat rapidly when placed in an alternating magnetic field (AMF), killing cells via hyperthermia. The mode of action is specific: no measurable cytotoxicity was observed for the particle without AMF or for AMF exposure without the particle.

**As featured in:**



B. Samanta, H. Yan, N. O. Fischer, J. Shi,  
D. J. Jerry and V. M. Rotello,  
*J. Mater. Chem.*, 2008, **18**, 1204.

23080793